Pressreleases

Sort by:

Filter by:

06 May 2011
Medpace Announces the Addition of Samer E Kaba, MD, Medical Director, Strengthening Therapeutic Expertise in Neuroscience Drug Development Services

By admin

Medpace, Inc. today announced the addition of Samer E. Kaba, MD, as a Medical Director with therapeutic expertise in guiding global clinical trials in the area of Neuroscience. Dr. Kaba brings a wealth of clinical development expertise in the areas of neurology, psychiatry, and analgesia. As a Medpace Medical Director, Dr. Kaba will be engaged with Medpace clients in formulating clinical development plans and strategy, designing clinical trials, and providing medical oversight for clinical trials in his areas of expertise. Dr. Kaba joins an experienced neurology operations team specifically in Parkinson’s, Alzheimer’s, multiple sclerosis, and pain.
06 May 2011
Medpace Reference Laboratories (MRL) central labs in China and India achieve CAP Accreditation

By admin

Medpace Reference Laboratories (MRL) central labs in China and India achieve CAP Accreditation, NGSP Level 1 and CDC Lipid Standardization Part III standardization, completing the company’s ability to deliver global, identical, highly standardized laboratory services in its own facilities.
06 May 2011
Symbios Clinical, a Medical Device CRO and Subsidiary of Medpace Changes Name to Medpace Medical Device, Concluding Integration Activities

By admin

Medpace, Inc. a global, full-service clinical research organization (CRO) announced that it has completed integration activities with Symbios Clinical, a CRO dedicated to medical device clinical trials which Medpace acquired earlier this year. Symbios Clinical will now be known as Medpace Medical Device (MMD) and will continue to provide expertise in pre-market, post-approval and postmarket / outcomes trials.
06 May 2011
Medpace Announces the Addition of Dr Jon Bruss, Medical Director, Adding Therapeutic Expertise in Infectious Disease, Antibiotics, Anti-Virals, Caccines, and Pediatric Medicines

By admin

Medpace, Inc. today announced the addition of Jon Bruss, MD, MSPH, MBA, FAAP, FIDSA as a Medical Director with therapeutic expertise in guiding global clinical trials in infectious disease. Dr. Bruss will combine therapeutic experience with existing Medpace clinical trial teams excellence to bring innovative anti-infective drugs to market in partnership with our sponsors.
06 May 2011
Medpace Announces the Addition of Dan Weng, MD, PhD, MA as Vice President, Rest of World

By admin

Medpace, Inc. today announced the addition of Dan Weng, MD, PhD, MA as Vice President, Rest of World (ROW) with responsibility for Asia, Pacific Rim, Latin America, and South Africa. Dr. Weng, an experienced clinical development professional, will be charged with driving global growth for Medpace in emerging markets. Emerging markets represent the fastest growing segment for drug development and clinical trials. The addition of Dr.Weng, along with existing Medpace clinical teams, will allow Medpace to provide deeper expertise in global development services for sponsors needing on-the-ground services in global markets.
06 May 2011
Medpace Medical Device (MMD) Announces the Addition of Diane Sahr, RN as Vice President, Clinical Affairs

By admin

Medpace, Inc. announced the addition of Diane Sahr, RN as a Vice President, Clinical Affairs for Medpace Medical Device, a wholly owned subsidiary of Medpace based in Minneapolis, MN. Medpace Medical Device conducts global clinical trials for both pre-market approval and post-market outcomes for medical device sponsors worldwide.
06 May 2011
Medpace Announces the Addition of Brian Murphy, MD, MPH, Medical Director, Strengthening Medpace’s Therapeutic Expertise in Infectious Disease and Pediatric Drug Development

By admin

Medpace, Inc. today announced the addition of Brian S. Murphy, MD, MPH as Medical Director with responsibility for leading clinical drug development for infectious disease and pediatric specific agents. The addition of Dr. Murphy, along with existing clinical and medical teams, will allow Medpace to provide deeper expertise in emerging therapeutic areas to bring innovative anti-infective and pediatric drugs to market in partnership with our sponsors.
05 May 2011
SCM Secures Phase II Aseptic Project

By admin

CLINICAL trial manufacturer SCM Pharma has secured a sterile filling and packaging project with Molteni Therapeutics, an Italian-based specialty pharmaceutical company, which involves a novel drug substance being developed for the topical treatment of infected skin lesions by using the therapeutic approach known as PhotoDynamic Therapy (PDT).
04 May 2011
Andy Black Reappointed as Kinapse Chief Executive

By admin

The Board of Directors of Kinapse Ltd. today announced that Andy Black has been appointed to succeed Shalabh Kumar as Chief Executive Officer, effective immediately.
04 May 2011
Chris Brinsmead Joins the Board of Kinapse UK

By admin

The Board of Directors of Kinapse Ltd. is delighted to announce that Chris Brinsmead has agreed to become a Non-Executive Director of Kinapse. Chris has had a long and distinguished career in the pharmaceutical industry, notably with Astra Zeneca where he was the President of their UK business. He has also recently served as President of the Association of the British Pharmaceutical Industry (ABPI).

Drug Discovery

Research & Development

Astellas and AI Proteins sign miniprotein therapeutics deal

Sanofi and ScionxBio partner on mRNA therapies

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG

Gerresheimer at CPHI Frankfurt 2025

Suppliers

No data found

Pressreleases

Medpace Announces the Addition of Samer E Kaba, MD, Medical Director, Strengthening Therapeutic Expertise in Neuroscience Drug Development Services

Medpace Reference Laboratories (MRL) central labs in China and India achieve CAP Accreditation

Symbios Clinical, a Medical Device CRO and Subsidiary of Medpace Changes Name to Medpace Medical Device, Concluding Integration Activities

Medpace Announces the Addition of Dr Jon Bruss, Medical Director, Adding Therapeutic Expertise in Infectious Disease, Antibiotics, Anti-Virals, Caccines, and Pediatric Medicines

Medpace Announces the Addition of Dan Weng, MD, PhD, MA as Vice President, Rest of World

Medpace Medical Device (MMD) Announces the Addition of Diane Sahr, RN as Vice President, Clinical Affairs

Medpace Announces the Addition of Brian Murphy, MD, MPH, Medical Director, Strengthening Medpace’s Therapeutic Expertise in Infectious Disease and Pediatric Drug Development

SCM Secures Phase II Aseptic Project

Andy Black Reappointed as Kinapse Chief Executive

Chris Brinsmead Joins the Board of Kinapse UK

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found

Search